Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TARS

Tarsus Pharmaceuticals Inc

Feb 13 • 04:00PM ET

60.78

-2.47 -3.91 %

Healthcare • Biotechnology • USA • NASD

Peers: XENE FOLD RDUS VKTX SRPT AXSM BTAI PRTA APLT PTCT

| Held by: VTI IWM VXF IWO IBB VTWO SCHA PJP VHT IHE

Index	RUT	P/E	-	EPS (ttm)	-2.01	Insider Own	7.72%	Shs Outstand	42.45M	Perf Week	-5.94%
Market Cap	2.58B	Forward P/E	31.61	EPS next Y	1.92	Insider Trans	-2.59%	Shs Float	39.17M	Perf Month	-19.21%
Enterprise Value	2.26B	PEG	-	EPS next Q	-0.07	Inst Own	104.14%	Short Float	14.84%	Perf Quarter	-18.75%
Income	-81.16M	P/S	7.05	EPS this Y	53.08%	Inst Trans	-6.52%	Short Ratio	10.49	Perf Half Y	12.26%
Sales	366.10M	P/B	7.70	EPS next Y	233.49%	ROA	-17.82%	Short Interest	5.81M	Perf YTD	-25.77%
Book/sh	7.89	P/C	6.42	EPS next 5Y	-	ROE	-28.35%	52W High	85.25 -28.70%	Perf Year	16.37%
Cash/sh	9.47	P/FCF	-	EPS past 3/5Y	-65.92% -67.97%	ROIC	-19.44%	52W Low	38.51 57.83%	Perf 3Y	302.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.49% -	Gross Margin	93.26%	Volatility	5.44% 4.84%	Perf 5Y	63.56%
Dividend TTM	-	EV/Sales	6.18	EPS Y/Y TTM	47.21%	Oper. Margin	-23.88%	ATR (14)	3.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.25	Sales Y/Y TTM	182.44%	Profit Margin	-22.17%	RSI (14)	29.44	Recom	1.30
Dividend Gr. 3/5Y	- -	Current Ratio	4.29	EPS Q/Q	51.59%	SMA20	-8.39%	Beta	0.59	Target Price	90.10
Payout	-	Debt/Eq	0.25	Sales Q/Q	146.68%	SMA50	-18.35%	Rel Volume	1.01	Prev Close	63.25
Employees	323	LT Debt/Eq	0.25	Earnings	Nov 04 AMC	SMA200	2.58%	Avg Volume	554.22K	Price	60.78
IPO	Oct 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.14% 3.01%	Trades		Volume	557,174	Change	-3.91%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$100
Nov-20-25	Initiated	Mizuho	Outperform	$100
Jun-02-25	Resumed	Oppenheimer	Outperform	$75
May-27-25	Resumed	H.C. Wainwright	Buy	$72
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Feb-02-26 12:27PM	Will Declining Medical Customers Affect Cigna's Q4 Earnings? (Zacks)
Jan-26-26 09:35AM	Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) (Zacks)
Jan-13-26 11:40AM	BMRN or TARS: Which Is the Better Value Stock Right Now? (Zacks)
Nov-24-25 04:30PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-05-25 05:05PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
12:04AM	Loading…
12:04AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-04-25 05:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Nov-03-25 07:31AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-28-25 05:00PM	Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-09-25 09:27AM	Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 06:41AM	Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Aug-27-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 06:33PM	3 Biotech Catalysts Present Major Opportunity (MarketBeat)
Aug-15-25 10:04AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily)
02:48PM	Loading…
Aug-14-25 02:48PM	Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point. (Investor's Business Daily)
Aug-06-25 06:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.15%
04:05PM	Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-05-25 09:48AM	Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result (GuruFocus.com)
Jul-30-25 05:00PM	Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
May-29-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:45AM	Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-08-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-05-25 06:04PM	Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts (Insider Monkey)
May-02-25 03:17AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com) -5.84%
May-01-25 09:37PM	Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? (Zacks)
10:00AM	Loading…
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-24-25 05:00PM	Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (GlobeNewswire)
11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks)
08:31AM	Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting (GlobeNewswire)
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-12-25 09:49PM	Tarsus Announces Pricing of Upsized $125.0 Million Public Offering (GlobeNewswire)
04:12PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Mar-06-25 05:00PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire) +6.66%
Feb-26-25 02:13AM	Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-25-25 08:40AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
01:31AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 05:00PM	Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 (GlobeNewswire)
Jan-30-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-20-25 03:31PM	Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Jan-14-25 09:35AM	Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround (Zacks) -5.72%
Jan-13-25 08:30AM	Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care (GlobeNewswire) -10.76%
Dec-26-24 10:30AM	How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run (Investor's Business Daily)
Dec-04-24 09:55AM	Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet (Zacks)
Nov-18-24 09:55AM	Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade (Zacks)
Nov-14-24 02:15AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-13-24 05:30PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
08:30AM	Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors (GlobeNewswire)
Nov-07-24 10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Nov-06-24 04:30PM	Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 (GlobeNewswire)
Nov-05-24 08:30AM	Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer (GlobeNewswire)
Oct-30-24 06:39AM	Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-24 08:30AM	Tarsus Launches Your Mitey Problem, the First Direct-to-Consumer TV Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% (GlobeNewswire)
Oct-09-24 05:56PM	Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ... (GuruFocus.com)
Sep-25-24 05:00PM	Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 (GlobeNewswire)
Aug-28-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference (GlobeNewswire)
Aug-08-24 09:56PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +13.72%
06:05PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
Jul-29-24 04:30PM	Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
May-29-24 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference (GlobeNewswire) -8.86% +8.70%
12:48PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:06AM	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating (MT Newswires)
03:49AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-08-24 08:58PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
May-06-24 09:55AM	Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect? (Zacks)
May-01-24 05:00PM	Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 (GlobeNewswire) +6.59%
Apr-23-24 08:30AM	Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon (GlobeNewswire)
Apr-09-24 07:35AM	5 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 09:55AM	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know (Zacks)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why (Zacks)
Mar-06-24 09:55AM	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% (Zacks)
Mar-05-24 04:30PM	Tarsus to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Tarsus Introduces Mite Party Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis (GlobeNewswire)
Mar-01-24 12:07AM	Tarsus Announces Pricing of $100.0 Million Public Offering (GlobeNewswire)
Feb-29-24 04:37PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Feb-28-24 12:00PM	Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy (Zacks)
09:58AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:13PM	Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +18.28%
06:34AM	Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
06:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Feb-22-24 08:00AM	Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease (GlobeNewswire)
Feb-20-24 05:00PM	Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 (GlobeNewswire)
Jan-31-24 05:00PM	Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference (GlobeNewswire) +6.17%
Jan-30-24 04:06AM	Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last? (Zacks)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Whitfield Dianne C.	Chief Human Resources Officer	Jan 02 '26	Sale	80.67	15,565	1,255,684	23,393	Jan 06 04:05 PM
Whitfield Dianne C.	Officer	Jan 02 '26	Proposed Sale	81.38	15,565	1,266,680		Jan 02 11:22 AM
Azamian Bobak R.	President/CEO and Board Chair	Dec 24 '25	Sale	82.51	6,000	495,089	857,991	Dec 30 04:26 PM
BOBAK AZAMIAN	OFFICER	Dec 24 '25	Proposed Sale	82.51	6,000	495,089		Dec 29 12:22 PM
Whitfield Dianne C.	Chief Human Resources Officer	Dec 16 '25	Sale	80.10	7,397	592,500	38,958	Dec 18 04:09 PM
LINK WILLIAM J PHD	Director	Dec 15 '25	Sale	81.43	12,500	1,017,816	128,832	Dec 17 04:07 PM
LINK WILLIAM J PHD	Director	Dec 15 '25	Sale	81.07	10,446	846,862	0	Dec 17 04:07 PM
Lin Elizabeth Yeu	Chief Medical Officer	Dec 16 '25	Sale	79.50	2,078	165,201	21,941	Dec 17 04:07 PM
Lin Elizabeth Yeu	Officer	Dec 16 '25	Proposed Sale	79.50	2,078	165,202		Dec 16 03:12 PM
Whitfield Dianne C.	Officer	Dec 16 '25	Proposed Sale	80.10	7,397	592,500		Dec 16 10:11 AM
William Link	Director	Dec 15 '25	Proposed Sale	81.02	10,446	846,340		Dec 15 04:38 PM
WILLIAM J LINK	DIRECTOR	Dec 15 '25	Proposed Sale	81.42	12,500	1,017,800		Dec 15 04:08 PM
Azamian Bobak R.	President/CEO and Board Chair	Sep 24 '25	Sale	55.37	6,000	332,220	812,106	Sep 26 04:08 PM
Bobak Azamian Living Trust	Officer	Sep 24 '25	Proposed Sale	55.37	6,000	332,208		Sep 24 04:57 PM
LINK WILLIAM J PHD	Director	Sep 08 '25	Sale	57.00	27,116	1,545,612	143,332	Sep 10 05:03 PM
LINK WILLIAM J PHD	Director	Sep 08 '25	Proposed Sale	57.01	27,116	1,546,000		Sep 08 04:19 PM
Azamian Bobak R.	President/CEO and Board Chair	Aug 11 '25	Sale	50.00	6,000	300,000	818,106	Aug 13 04:32 PM
Azamian Bobak R.	Officer	Aug 11 '25	Proposed Sale	50.00	6,000	300,000		Aug 11 12:43 PM
Farrow Jeffrey S	See Remarks	Jun 17 '25	Sale	40.42	13,608	550,035	36,704	Jun 18 04:07 PM
Farrow Jeffrey S	Officer	Jun 17 '25	Proposed Sale	40.42	13,608	550,088		Jun 17 04:14 PM
Lin Elizabeth Yeu	Chief Medical Officer	Jun 16 '25	Sale	41.08	1,006	41,326	7,694	Jun 17 04:07 PM
Lin Elizabeth Yeu	Officer	Jun 16 '25	Proposed Sale	41.07	1,006	41,321		Jun 16 03:07 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 09 '25	Sale	43.76	17,500	765,800	47,557	Jun 11 04:50 PM
Mottiwala Aziz	Officer	Jun 09 '25	Proposed Sale	44.74	17,500	782,950		Jun 09 10:21 AM
Azamian Bobak R.	President/CEO and Board Chair	Mar 24 '25	Sale	50.00	6,000	300,000	824,106	Mar 26 04:47 PM
Azamian Bobak R.	Officer	Mar 24 '25	Proposed Sale	50.00	6,000	300,000		Mar 24 05:35 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '25	Sale	46.29	3,643	168,634	71,979	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 20 '25	Sale	50.11	3,365	168,620	65,057	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 19 '25	Sale	47.40	3,557	168,602	68,422	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 20 '25	Sale	50.11	2,435	122,018	79,682	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '25	Sale	46.29	2,605	120,585	84,660	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 19 '25	Sale	47.40	2,543	120,538	82,117	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 18 '25	Sale	46.29	3,341	154,655	58,057	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 19 '25	Sale	47.40	3,261	154,571	54,796	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 20 '25	Sale	50.11	3,084	154,539	51,712	Mar 20 09:49 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '25	Sale	46.29	2,315	107,161	50,751	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 20 '25	Sale	50.11	2,137	107,085	46,355	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 19 '25	Sale	47.40	2,259	107,077	48,492	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 20 '25	Sale	50.11	8,534	427,639	53,635	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 19 '25	Sale	47.40	8,551	405,317	62,169	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '25	Sale	46.29	7,131	330,094	70,720	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 19 '25	Sale	47.40	1,254	59,440	23,617	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 18 '25	Sale	46.29	1,284	59,436	24,871	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 20 '25	Sale	50.11	1,186	59,430	22,431	Mar 20 09:48 PM
Whitfield Dianne C.	Officer	Mar 20 '25	Proposed Sale	50.11	2,137	107,093		Mar 20 04:35 PM
Farrow Jeffrey S	Officer	Mar 20 '25	Proposed Sale	50.11	1,186	59,435		Mar 20 04:30 PM
Mottiwala Aziz	Officer	Mar 20 '25	Proposed Sale	50.11	3,365	168,632		Mar 20 04:29 PM
Wahl Bryan	Officer	Mar 20 '25	Proposed Sale	50.11	3,084	154,550		Mar 20 04:21 PM
Neervannan Seshadri	Officer	Mar 20 '25	Proposed Sale	50.11	2,435	122,026		Mar 20 04:18 PM
Azamian Bobak R.	Officer	Mar 20 '25	Proposed Sale	50.11	8,534	427,669		Mar 20 04:11 PM
Neervannan Seshadri	Officer	Mar 19 '25	Proposed Sale	47.40	2,543	120,536		Mar 19 03:27 PM
Wahl Bryan	Officer	Mar 19 '25	Proposed Sale	47.40	3,261	154,569		Mar 19 03:24 PM
Azamian Bobak R.	Officer	Mar 19 '25	Proposed Sale	47.40	8,551	405,311		Mar 19 03:23 PM
Whitfield Dianne C.	Officer	Mar 19 '25	Proposed Sale	47.40	2,259	107,075		Mar 19 03:22 PM
Farrow Jeffrey S	Officer	Mar 19 '25	Proposed Sale	47.40	1,254	59,439		Mar 19 03:12 PM
Mottiwala Aziz	Officer	Mar 19 '25	Proposed Sale	47.40	3,557	168,599		Mar 19 03:12 PM
Neervannan Seshadri	Officer	Mar 18 '25	Proposed Sale	46.28	2,605	120,571		Mar 18 04:31 PM
Wahl Bryan	Officer	Mar 18 '25	Proposed Sale	46.28	3,341	154,637		Mar 18 04:26 PM
Mottiwala Aziz	Officer	Mar 18 '25	Proposed Sale	46.28	3,643	168,614		Mar 18 04:26 PM
Whitfield Dianne C.	Officer	Mar 18 '25	Proposed Sale	46.28	2,315	107,149		Mar 18 04:20 PM
Azamian Bobak R.	Officer	Mar 18 '25	Proposed Sale	46.28	7,131	330,055		Mar 18 04:15 PM
Farrow Jeffrey S	Officer	Mar 18 '25	Proposed Sale	46.28	1,284	59,429		Mar 18 04:12 PM
Goldberg Andrew D.	Director	Mar 07 '25	Option Exercise	12.89	7,000	90,230	13,350	Mar 11 04:01 PM

Open in Screener

RXST

RxSight Inc

Feb 13 • 04:00PM ET

8.04

+0.24 3.08 %

Healthcare • Medical Devices • USA • NASD

Peers: STAA ALGN ICUI EW BSX MDT SYK TFX BAX XRAY

| Held by: VTI IWM VXF IWO VTWO SCHA VHT XHE DFAS ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.88	Insider Own	6.26%	Shs Outstand	41.08M	Perf Week	-4.17%
Market Cap	330.58M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	0.00%	Shs Float	38.54M	Perf Month	-16.86%
Enterprise Value	114.62M	PEG	-	EPS next Q	-0.33	Inst Own	82.75%	Short Float	10.75%	Perf Quarter	-19.68%
Income	-35.73M	P/S	2.33	EPS this Y	-50.09%	Inst Trans	-12.37%	Short Ratio	4.35	Perf Half Y	-2.19%
Sales	142.09M	P/B	1.20	EPS next Y	-4.03%	ROA	-11.54%	Short Interest	4.14M	Perf YTD	-22.84%
Book/sh	6.72	P/C	1.45	EPS next 5Y	-14.11%	ROE	-12.92%	52W High	32.24 -75.07%	Perf Year	-74.77%
Cash/sh	5.53	P/FCF	-	EPS past 3/5Y	26.50% -	ROIC	-12.48%	52W Low	6.32 27.22%	Perf 3Y	-39.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	83.64% 128.61%	Gross Margin	74.98%	Volatility	5.76% 6.09%	Perf 5Y	-
Dividend TTM	-	EV/Sales	0.81	EPS Y/Y TTM	-7.15%	Oper. Margin	-32.01%	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.44	Sales Y/Y TTM	10.75%	Profit Margin	-25.15%	RSI (14)	35.76	Recom	3.09
Dividend Gr. 3/5Y	- -	Current Ratio	12.74	EPS Q/Q	-50.41%	SMA20	-8.60%	Beta	1.15	Target Price	10.39
Payout	-	Debt/Eq	0.04	Sales Q/Q	-14.09%	SMA50	-21.88%	Rel Volume	0.54	Prev Close	7.80
Employees	498	LT Debt/Eq	0.04	Earnings	Feb 25 AMC	SMA200	-23.09%	Avg Volume	952.22K	Price	8.04
IPO	Jul 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.12% 19.87%	Trades		Volume	509,526	Change	3.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Initiated	William Blair	Mkt Perform
Jul-15-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$9
Jul-10-25	Downgrade	Jefferies	Buy → Hold	$9
Jul-09-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$9
Jul-09-25	Downgrade	Oppenheimer	Outperform → Perform
Jul-09-25	Downgrade	BTIG Research	Buy → Neutral
May-19-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$25
Apr-15-25	Initiated	Piper Sandler	Neutral	$18
Apr-09-25	Downgrade	UBS	Buy → Neutral	$16
Apr-04-25	Downgrade	JP Morgan	Overweight → Underweight	$40 → $17
Apr-03-25	Downgrade	BofA Securities	Buy → Underperform	$36 → $22
Dec-20-24	Downgrade	Stifel	Buy → Hold	$65 → $40
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$56 → $42
Dec-06-24	Initiated	UBS	Buy	$52
Oct-29-24	Initiated	Jefferies	Buy	$72
Aug-20-24	Reiterated	Needham	Buy	$54 → $66
Aug-06-24	Reiterated	Needham	Buy	$75 → $54
May-07-24	Reiterated	BTIG Research	Buy	$61 → $72
Dec-13-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$31 → $42
Dec-12-23	Initiated	Stifel	Buy	$40

Show Previous Ratings

Feb-11-26 04:10PM	RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (GlobeNewswire)
03:15PM	RxSight, Inc. (RXST) Initiated at Market Perform as Firm Seeks Sales Reacceleration (Insider Monkey)
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
Jan-13-26 06:16AM	RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-11-26 09:30AM	RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer (GlobeNewswire)
04:05PM	Loading…
Jan-02-26 04:05PM	RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-25 12:42PM	RxSight CFO exit raises concerns over pace of recovery, BTIG says (Investing.com) -9.98%
Dec-22-25 05:15PM	RxSight, Inc. Announces Chief Financial Officer Transition (GlobeNewswire)
Nov-20-25 04:05PM	RxSight, Inc. to Present at the Piper Sandler Healthcare Conference (GlobeNewswire) -5.79% +13.41%
Nov-06-25 12:04AM	RxSight Inc (RXST) Q3 2025 Earnings Call Highlights: Navigating Growth Amid Revenue Challenges (GuruFocus.com)
Nov-05-25 06:50PM	RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.33%
04:05PM	RxSight, Inc. Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:31AM	RxSight Inc (RXST) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-22-25 04:05PM	RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-16-25 04:05PM	RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting (GlobeNewswire) +7.34%
08:45AM	Loading…
Sep-16-25 08:45AM	Investors in RxSight, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - RXST (PR Newswire)
Sep-15-25 09:32AM	RxSight (RXST) Fell Due to Missed Expectations and Guidance Reduction (Insider Monkey)
Sep-09-25 09:00AM	RxSight, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - RXST (PR Newswire) +9.40%
Sep-05-25 04:09PM	Investors in RxSight, Inc. (RXST): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile)
Sep-04-25 03:59PM	Investors Urged to Contact Levi & Korsinsky for Information Before September 22, 2025 - RxSight, Inc. (RXST) (Newsfile)
Aug-25-25 04:05PM	RxSight, Inc. to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire) -7.22%
Aug-22-25 08:45AM	RxSight, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RXST (PR Newswire) +6.30%
Aug-14-25 04:05PM	RxSight, Inc. to Present at the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-25 05:14PM	Investors in RxSight, Inc. (RXST): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile) +13.06%
Aug-12-25 09:00AM	RxSight, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RXST (PR Newswire) +10.53%
Aug-07-25 06:15PM	RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.70%
04:05PM	RxSight, Inc. Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 08:05AM	RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors (GlobeNewswire)
Aug-01-25 09:00AM	RxSight, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - RXST (PR Newswire)
Jul-31-25 04:15PM	Investors in RxSight, Inc. (RXST): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile)
04:02PM	Loading…
Jul-30-25 04:02PM	Investors in RxSight, Inc. (RXST): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile)
Jul-25-25 04:54PM	RxSight, Inc. (RXST) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 22, 2025 (Newsfile)
Jul-24-25 04:05PM	RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-09-25 03:00AM	RxSight Inc (RXST) Q2 2025 Earnings Call Highlights: Strategic Shifts Amid Market Challenges (GuruFocus.com) -37.84%
Jul-08-25 04:05PM	RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance (GlobeNewswire)
Jul-04-25 11:40AM	FMS vs. RXST: Which Stock Is the Better Value Option? (Zacks)
Jun-18-25 11:40AM	KMDA vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
11:40AM	FMS or RXST: Which Is the Better Value Stock Right Now? (Zacks)
May-31-25 05:59AM	Down Over 30%: Wells Fargo Says Now Is the Time to Load Up on These 2 Beaten-Down Stocks (TipRanks)
May-23-25 08:32AM	Do Options Traders Know Something About RxSight Stock We Don't? (Zacks)
May-20-25 04:10PM	RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum (GlobeNewswire)
10:55AM	Wells Fargo Upgrades RxSight (RXST), Sees LAL Technology as Undervalued (Insider Monkey)
May-08-25 03:31AM	RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Advances Amid ... (GuruFocus.com) -11.21%
May-07-25 11:04PM	RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript (Seeking Alpha) +6.81%
07:55PM	RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	RxSight, Inc. Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-30-25 04:05PM	RxSight, Inc. to Present at the Bank of America Healthcare Conference (GlobeNewswire)
10:01AM	RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-23-25 04:05PM	RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-04-25 11:46AM	JP Morgan downgrades RxSight on market, competitive pressures (Investing.com)
09:40AM	Block upgraded, Nvidia downgraded: Wall Streets top analyst calls (TipRanks)
03:00AM	RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ... (GuruFocus.com)
Apr-03-25 10:39PM	Preliminary Q1 2025 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents) -37.94%
05:57PM	?RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) (Seeking Alpha)
03:54PM	RxSight, Inc. (RXST) Q1 2025 Preliminary Results Conference Call (Transcript) (Seeking Alpha)
12:59PM	RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock (GuruFocus.com)
07:32AM	RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges (Benzinga)
Apr-02-25 08:00PM	RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance (GlobeNewswire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-25-25 04:05PM	RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Feb-26-25 02:15AM	RxSight Inc (RXST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Feb-25-25 05:55PM	RxSight, Inc. (RXST) Misses Q4 Earnings Estimates (Zacks)
04:05PM	RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance (GlobeNewswire)
01:36AM	What To Expect From RxSight Inc (RXST) Q4 2024 Earnings (GuruFocus.com)
Feb-11-25 04:10PM	RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025 (GlobeNewswire)
Jan-18-25 07:55AM	RxSight price target lowered to $43 from $66 at Needham (TipRanks)
Jan-12-25 09:30AM	RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance (GlobeNewswire)
Jan-02-25 04:05PM	RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-24 09:43AM	Do You Believe in the Long-Term Growth Potential of RxSight (RXST)? (Insider Monkey) -11.86%
Nov-20-24 12:00PM	RxSight (RXST) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-08-24 12:02PM	RxSight Inc (RXST) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Market ... (GuruFocus.com) -5.59%
Nov-07-24 07:00PM	RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3 (Zacks) -7.09%
04:05PM	RxSight, Inc. Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 07:16AM	What To Expect From RxSight Inc (RXST) Q3 2024 Earnings (GuruFocus.com) +5.80%
Oct-24-24 04:05PM	RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024 (GlobeNewswire)
Oct-15-24 06:10PM	RxSight, Inc. (RXST): A Visionary Small-Cap Stock Pick by Hedge Funds (Insider Monkey)
Oct-13-24 05:33PM	RxSight, Inc. (RXST): Top Investors Are Investing In This Small-Cap Stock Now (Insider Monkey)
Aug-22-24 04:05PM	RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences (GlobeNewswire)
Aug-19-24 03:43PM	RxSight Stock Sees Relative Strength Rating Rise To 91 (Investor's Business Daily)
Aug-12-24 09:55AM	Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect? (Zacks)
Aug-06-24 09:55AM	Q2 2024 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents) +17.34%
Aug-05-24 06:10PM	RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2 (Zacks)
04:05PM	RxSight, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
11:20AM	The 3 Best Med Tech Stocks to Buy Now (InvestorPlace)
Jul-29-24 09:35AM	Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround (Zacks)
Jul-22-24 04:05PM	RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024 (GlobeNewswire)
Jul-12-24 09:35AM	RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jul-10-24 10:59AM	Dow Flat As Nasdaq, S&P 500 Rise Again; Gold Stocks Rally, But These Growth Players Get Hit (Live Coverage) (Investor's Business Daily) -10.32%
Jun-18-24 01:50AM	Insider Sale: Director Julie Andrews Sells 15,625 Shares of RxSight Inc (RXST) (GuruFocus.com)
Jun-13-24 11:22AM	Eye Care Innovator In Buy Zone; 176% Growth Expected For IBD 50 Stock (Investor's Business Daily)
Jun-07-24 02:40PM	These 5 Companies Lost Money. Here's Why They're Still On The IBD 50. (Investor's Business Daily)
Jun-05-24 04:05PM	RxSight, Inc. To Participate in the Truist Securities Medtech Conference (GlobeNewswire)
May-30-24 04:00AM	Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board (GlobeNewswire)
May-28-24 12:00PM	What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now? (Zacks)
May-24-24 11:40AM	Why Top-Rated Medtech RxSight Has 20/20 Vision And Is Seeing 50% Growth (Investor's Business Daily)
May-13-24 04:58PM	RxSight Raises $115 Million From Public Offering of Shares (MT Newswires)
04:05PM	RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-08-24 09:15PM	RxSight, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:05PM	RxSight, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goldshleger Ilya	See remarks	Sep 25 '25	Option Exercise	4.27	23,445	99,998	65,691	Sep 26 04:07 PM
Weinberg Eric	See remarks	Jun 02 '25	Option Exercise	3.93	188,002	738,848	195,351	Jun 03 06:18 PM
Thunen Shelley B	See remarks	Apr 14 '25	Option Exercise	4.34	7,792	33,806	38,354	Apr 15 08:57 PM
Fountain Tamara	Director	Mar 12 '25	Sale	25.71	7,000	180,002	24,793	Mar 13 04:46 PM
TAMARA R FOUNTAIN	Director	Mar 12 '25	Proposed Sale	25.71	7,000	180,002		Mar 12 04:02 PM

TARS

Tarsus Pharmaceuticals Inc

RXST

RxSight Inc

Upgrade your FINVIZ experience